ViroStatics’ Chief Development Officer, Dr. Michael Stevens, to Present During Rodman & Renshaw's Tenth Annual Global Healthcare Conference on November 12, 2008

SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--ViroStatics, srl today announced Chief Development Officer Dr. Michael Stevens will present a Company overview during Rodman & Renshaw's Tenth Annual Global Healthcare Conference taking place November 10 through 12, 2008 at the New York Palace Hotel. Rodman & Renshaw is a leading investment banking firm with particular emphasis on "essential" industries, including health care. The conference, which also features a keynote address by former U.S. President, Bill Clinton, hosts more than 550 companies from across the globe presenting to over 1000 registered institutional investors.

ViroStatics’ presentation takes place on Wednesday, November 12^th at 4:05 PM (EST) in the Louis Room during which Dr. Stevens will review and update the Company's recent developments in drug discovery and development as well as the development of proprietary biomarker assays. In the presentation, Dr. Stevens will review how virostatic drugs represent a new family of antivirals designed not only to suppress viruses but also to preserve the immune system from chronic damage. In particular, he will present the Company’s lead developmental product, VS411 - a fixed combination of virostatic drugs undergoing Phase II clinical development for the treatment of HIV believed to be the first in this new class of drugs.

About ViroStatics

ViroStatics srl, an Italian pharmaceutical company with operations in Sassari and Pavia, Italy and Princeton, NJ, is committed to discovering and developing novel combination therapeutics to address significant medical needs in HIV/AIDS, chronic infections and related fields. The company is developing its lead product, VS411, as the first fixed-dose combination of two drugs that not only decrease HIV replication but also protect and conserve the immune system. VS411 has completed Phase I and is now undergoing evaluation in a multinational Phase II development program. ViroStatics has also developed novel biomarker assays and a proprietary screening methodology to rapidly and efficiently identify cytostatic agents with potential to inhibit viral replication and control the over-stimulation of the immune system that is believed to drive the progression of HIV to AIDS. ViroStatics is committed to expanding its pipeline and product portfolio by in-licensing early- and late-stage compounds and exploring co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals.